Merck Expands Bengaluru Facility with €13 Million Investment

Merck has invested €13 million in its Jigani facility in Bengaluru to strengthen local production of chemistry and biology materials for India's life science sector and customers across the Asia-Pacific region. The expansion will add biological buffer manufacturing to the site's established chemistry capabilities, providing integrated offerings for research, diagnostics, biotechnology, and biopharmaceutical manufacturing.

The facility has reserved 34 per cent of its site area for greenbelt, including trees and vegetation that support environmental protection and sustainable operations. The expansion will enable faster responses to customers' scientific and manufacturing needs by improving supply reliability and reducing import dependence.

Dhananjay Singh, Managing Director of Merck's Life Science business in India, said, 'India is emerging as an increasingly important hub for life science innovation and manufacturing.' He added that the investment will reinforce the global supply chain and support the 'Make in India' initiative.